Westhofen Thilo, Eismann Lennert, Buchner Alexander, Schlenker Boris, Giessen-Jung Clemens, Becker Armin, Stief Christian G, Kretschmer Alexander
Department of Urology, Ludwig-Maximilians University, Munich, Germany.
Department of Urology, Ludwig-Maximilians University, Munich, Germany.
Eur Urol Focus. 2022 Nov;8(6):1659-1665. doi: 10.1016/j.euf.2022.02.001. Epub 2022 Feb 17.
It has been shown that baseline health-related quality of life (HRQOL) is a valuable prognostic indicator of survival outcomes for various metastatic cancers, but there is no evidence on the prognostic value of baseline HRQOL for patients with bladder cancer undergoing radical cystectomy (RC) and ileal conduit (IC) or orthotopic ileal neobladder (ONB) with curative intent.
To assess the association between baseline HRQOL and survival outcomes following RC.
DESIGN, SETTING, AND PARTICIPANTS: The study included 407 patients with prospectively assessed baseline HRQOL before RC. Patients were stratified according to the Global Health Status (GHS) domain of the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire, with good general HRQOL defined as GHS ≥70 on the basis of validated cutoff levels. A propensity score-matched analysis of 357 patients (1:2 ratio; 125 patients with GHS ≥70 vs 232 with GHS <70) was performed.
RC with IC or ONB.
The primary endpoint was cancer-specific survival (CSS). The secondary endpoints were overall survival (OS) and recurrence-free survival (RFS). Kaplan-Meier and multivariate Cox regression models were constructed to assess the prognostic value of baseline GHS for prediction of survival outcomes.
Median follow-up was 40.5 mo. The rates of 5-yr CSS (82% vs 65%; p = 0.001), 5-yr OS (76% vs 53%; p = 0.001), and 5-yr RFS (50% vs 39%; p = 0.04) were significantly higher in the GHS ≥70 cohort. GHS ≥70 was confirmed as an independent predictor for CSS (hazard ratio [HR] 0.37, 95% confidence interval [CI] 0.18-0.73; p = 0.004), OS (HR 0.45, 95% CI 0.26-0.79; p = 0.005), and RFS (HR 0.50, 95% CI 0.30-0.83; p = 0.008) in multivariate analyses. Study limitations include the retrospective analysis of prospectively collected data and use of a HRQOL questionnaire not specifically for bladder cancer.
Our findings suggest that preoperative baseline HRQOL has significant predictive value for outcomes of RC with curative intent for bladder cancer. We found that good general HRQOL at baseline accurately predicts greater CSS, OS, and RFS.
We assessed the association between health-related quality of life at baseline and survival outcomes after radical cystectomy for bladder cancer. We found that good general health-related quality of life at baseline predicts better survival outcomes and that higher baseline scores were associated with greater cancer-specific survival.
已有研究表明,基线健康相关生活质量(HRQOL)是多种转移性癌症生存结局的重要预后指标,但尚无证据表明基线HRQOL对接受根治性膀胱切除术(RC)及回肠膀胱术(IC)或原位回肠新膀胱术(ONB)且有治愈意向的膀胱癌患者的预后价值。
评估基线HRQOL与RC术后生存结局之间的关联。
设计、背景与参与者:本研究纳入了407例在RC术前对基线HRQOL进行前瞻性评估的患者。根据欧洲癌症研究与治疗组织QLQ-C30问卷的全球健康状况(GHS)领域对患者进行分层,基于验证的临界值,将总体HRQOL良好定义为GHS≥70。对357例患者进行了倾向评分匹配分析(1:2比例;125例GHS≥70的患者与232例GHS<70的患者)。
行IC或ONB的RC术。
主要终点为癌症特异性生存(CSS)。次要终点为总生存(OS)和无复发生存(RFS)。构建Kaplan-Meier和多变量Cox回归模型,以评估基线GHS对生存结局预测的预后价值。
中位随访时间为40.5个月。GHS≥70组的5年CSS率(82%对65%;p = 0.001)、5年OS率(76%对53%;p = 0.001)和5年RFS率(50%对39%;p = 0.04)显著更高。在多变量分析中,GHS≥70被确认为CSS(风险比[HR] 0.37,95%置信区间[CI] 0.18 - 0.73;p = 0.004)、OS(HR 0.45,95% CI 0.26 - 0.79;p = 0.005)和RFS(HR 0.50,95% CI 0.30 - 0.83;p = 0.008)的独立预测因素。研究局限性包括对前瞻性收集数据的回顾性分析以及使用的并非专门针对膀胱癌的HRQOL问卷。
我们的研究结果表明,术前基线HRQOL对有治愈意向的膀胱癌RC术的结局具有显著预测价值。我们发现,基线时总体HRQOL良好可准确预测更高的CSS、OS和RFS。
我们评估了基线时健康相关生活质量与膀胱癌根治性膀胱切除术后生存结局之间的关联。我们发现,基线时总体健康相关生活质量良好可预测更好的生存结局,且更高的基线评分与更高的癌症特异性生存相关。